Managing Barrett's oesophagus

Hebbard, Geoffrey S; Nandurkar, Sanjay

doi:10.5694/j.1326-5377.2004.tb05987.x

Topics

Digestive system diseases

Neoplasms

Can chemoprevention reduce the risk of progression to malignancy?

1 Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, VIC.
2 Department of Gastroenterology, Box Hill Hospital, Box Hill, VIC.

Correspondence:

Competing interests:

G S H has acted as a consultant to AstraZeneca, Novartis and Pharmacia (Pfizer), and has received research support, sponsored travel and honoraria for speaking from AstraZeneca, Novartis and Wyeth. S N has acted in an advisory capacity to Pharmacia and has received research support, sponsored travel and honoraria for speaking from AstraZeneca and Pharmacia (Pfizer).

1. Falk GW. Barrett’s oesophagus. Gastroenterology 2002; 122: 1569-1591.
2. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333-338.
3. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98: 1931-1939.
4. Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett’s oesophagus: observational study. BMJ 2000; 321: 1252-1255.
5. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett’s oesophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001; 96: 3071-3083.
6. Triadafilopoulos G. Acid and bile reflux in Barrett’s esophagus: a tale of two evils. Gastroenterology 2001; 121: 1502-1506.
7. Souza RF, Spechler SJ. Barrett’s esophagus: chemoprevention. Gastrointest Endosc Clin N Am 2003; 13: 419-432.
8. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 2004; 180: 387-391. <eMJA full text>
9. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
10. Spechler SJ. Disputing dysplasia. Gastroenterology 2001; 120: 1864-1868.
11. Richter JE. Antireflux surgery and adenocarcinoma of the esophagus: let the truth be told. Gastroenterology 2001; 121: 1506-1508.
12. Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18 000 patients treated with omeprazole. Gut 2003; 52: 942-946.
13. Sampliner RE. Long-term endoscopic surveillance of Barrett’s esophagus. Am J Gastroenterol 2003; 98: 1912-1913.

Online responses are no longer available. Please refer to our instructions for authors page for more information.